Robust IPO activity in the final months of 2026 reflects a sustained recovery in capital markets, with multiple U.S. deals such as Retension Pharmaceuticals and TRex Bio scheduled to price in early October and a pipeline of fresh S-1 filings spanning biotech, AI-adjacent tech, and SPACs. Hong Kong listings have already raised over HK$388 billion year-to-date through Q3, more than doubling prior-year levels and positioning the market for a potential record HK$500 billion finish, while U.S. proceeds through mid-year exceeded $114 billion amid larger median deal sizes. Elevated Treasury yields near 19-year highs have prompted selective postponements, yet recent pricings and amendments demonstrate ongoing issuer access supported by institutional demand for scaled growth companies. Key near-term catalysts include additional October listings and regulatory timelines that could accelerate or delay Q4 flow before year-end resolution.